CN Patent

CN101072564A — 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途

Assigned to Encysive Pharmaceuticals Inc · Expires 2007-11-14 · 19y expired

What this patent protects

一般而言，本发明涉及包含内皮缩血管肽A受体(ET A )拮抗剂和磷酸二酯酶5(PDE5)抑制剂的联合疗法、包含ET A 拮抗剂和PDE5抑制剂的药物组合物和包括给予ET A 拮抗剂和PDE5抑制剂治疗不同疾病的方法。具体而言，该联合疗法和药物组合物适用于治疗和/或预防心脏病如肺动脉高血压(PAH)。

USPTO Abstract

一般而言，本发明涉及包含内皮缩血管肽A受体(ET A )拮抗剂和磷酸二酯酶5(PDE5)抑制剂的联合疗法、包含ET A 拮抗剂和PDE5抑制剂的药物组合物和包括给予ET A 拮抗剂和PDE5抑制剂治疗不同疾病的方法。具体而言，该联合疗法和药物组合物适用于治疗和/或预防心脏病如肺动脉高血压(PAH)。

Drugs covered by this patent

Patent Metadata

Patent number
CN101072564A
Jurisdiction
CN
Classification
—
Expires
2007-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Encysive Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.